Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases

Weiguanliu Zhang,Christina D. Orrú,Aaron Foutz,Mingxuan Ding,Jue Yuan,Syed Zahid Ali Shah,Jing Zhang,Keisi Kotobelli,Maria Gerasimenko,Tricia Gilliland,Wei Chen,Michelle Tang,Mark Cohen,Jiri Safar,Bin Xu,Dao-Jun Hong,Li Cui,Andrew G. Hughson,Lawrence B. Schonberger,Curtis Tatsuoka,Shu G. Chen,Justin J. Greenlee,Zerui Wang,Brian S. Appleby,Byron Caughey,Wen-Quan Zou
DOI: https://doi.org/10.1007/s00401-023-02661-2
IF: 15.887
2024-01-19
Acta Neuropathologica
Abstract:Definitive diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD) relies on the examination of brain tissues for the pathological prion protein (PrP Sc ). Our previous study revealed that PrP Sc -seeding activity (PrP Sc -SA) is detectable in skin of sCJD patients by an ultrasensitive PrP Sc seed amplification assay (PrP Sc -SAA) known as real-time quaking-induced conversion (RT-QuIC). A total of 875 skin samples were collected from 2 cohorts (1 and 2) at autopsy from 2–3 body areas of 339 cases with neuropathologically confirmed prion diseases and non-sCJD controls. The skin samples were analyzed for PrP Sc -SA by RT-QuIC assay. The results were compared with demographic information, clinical manifestations, cerebrospinal fluid (CSF) PrP Sc -SA, other laboratory tests, subtypes of prion diseases defined by the methionine (M) or valine (V) polymorphism at residue 129 of PrP, PrP Sc types (#1 or #2), and gene mutations in deceased patients. RT-QuIC assays of the cohort #1 by two independent laboratories gave 87.3% or 91.3% sensitivity and 94.7% or 100% specificity, respectively. The cohort #2 showed sensitivity of 89.4% and specificity of 95.5%. RT-QuIC of CSF available from 212 cases gave 89.7% sensitivity and 94.1% specificity. The sensitivity of skin RT-QuIC was subtype dependent, being highest in sCJDVV1-2 subtype, followed by VV2, MV1-2, MV1, MV2, MM1, MM1-2, MM2, and VV1. The skin area next to the ear gave highest sensitivity, followed by lower back and apex of the head. Although no difference in brain PrP Sc -SA was detected between the cases with false negative and true positive skin RT-QuIC results, the disease duration was significantly longer with the false negatives [12.0 ± 13.3 (months, SD) vs. 6.5 ± 6.4, p < 0.001]. Our study validates skin PrP Sc -SA as a biomarker for the detection of prion diseases, which is influenced by the PrP Sc types, PRNP 129 polymorphisms, dermatome sampled, and disease duration.
pathology,neurosciences,clinical neurology
What problem does this paper attempt to address?